Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.53 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.53 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.53 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.53 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.53 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CYP4F8 | P98187 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181635 | 0.89 | CYP1A1 (0.67) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL1180781 | 0.84 | APP (0.74) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL146457 | 0.81 | NOTUM (0.55) | CYP3A4MAPTRAB9ASMN1; SMN2TDP1 | |
| SCHEMBL1105472 | 0.81 | APP (0.76) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL25094618 | 0.81 | HDAC6 (0.55) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL9430000 | 0.81 | HDAC6 (0.55) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL12093643 | 0.81 | HDAC6 (0.55) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL147294 | 0.77 | HSD17B1 (0.49) | CYP3A4CYP2D6CYP2C19HSD17B2HSD17B1 | |
| SCHEMBL28523476 | 0.77 | HDAC6 (0.55) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL12177801 | 0.77 | HDAC6 (0.55) | HDAC6CYP1A1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081912-A2 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HDAC6 592/4885CYP1A1 151/4885CYP1A2 129/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HDAC6 592/4885CYP1A1 151/4885CYP1A2 129/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HDAC6 592/4885CYP1A1 151/4885CYP1A2 129/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HDAC6 592/4885CYP1A1 151/4885CYP1A2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.